{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:50:40Z","timestamp":1788306640664,"version":"build-2803163510"},"reference-count":39,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2020,4,26]],"date-time":"2020-04-26T00:00:00Z","timestamp":1587859200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Primary antifungal prophylaxis in paediatric allogeneic HSCT recipients is mainly based on azoles, which can have related toxicity and drug interactions. Low-dose liposomal amphotericin B (L-AmB) is an attractive intravenous alternative because of its low toxicity and lower risk of interactions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To evaluate the effectiveness and safety of L-AmB (1\u2009mg\/kg\/day) for primary antifungal prophylaxis in pre-engraftment paediatric HSCT patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and methods<\/jats:title><jats:p>Retrospective, observational study including all consecutive patients aged \u226418\u2009years who underwent HSCT and received antifungal prophylaxis with intravenous L-AmB (1\u2009mg\/kg\/day, from day \u22121 to 48\u2009h before discharge) between January 2012 and December 2016.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In total, 125 HSCT procedures in 118 patients were included, median age 7.2\u2009years (IQR 4.2\u201311.5). Haematological malignancies were the main underlying condition (63.6%), and 109 (87.2%) were considered at high risk for invasive fungal infection (IFI). Ten patients (7.7%), all high risk, developed breakthrough IFI (three Candida spp., seven invasive mould infections) and tended to have higher overall mortality. The only statistically significant risk factor for IFI was cytomegalovirus co-infection. Adverse events, all grade I, occurred in 25 (20%), requiring L-AmB withdrawal in one case. Overall survival at 30\u2009days was 99.2%. At study completion, one patient had died of IFI.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The incidence of breakthrough IFI was comparable to that of previous reports, with a very low rate of significant toxicity. Thus, prophylactic L-AmB may be a safe, effective option for antifungal prophylaxis in the pre-engraftment phase for children undergoing HSCT, even those at high risk.<\/jats:p><\/jats:sec>","DOI":"10.1093\/jac\/dkaa149","type":"journal-article","created":{"date-parts":[[2020,3,27]],"date-time":"2020-03-27T20:11:52Z","timestamp":1585339912000},"source":"Crossref","is-referenced-by-count":8,"title":["Low-dose liposomal amphotericin B for antifungal prophylaxis in paediatric allogeneic haematopoietic stem cell transplantation"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2035-8291","authenticated-orcid":false,"given":"Natalia","family":"Mendoza-Palomar","sequence":"first","affiliation":[{"name":"Paediatric Infectious Diseases and Immunodeficiencies Unit, University Hospital Vall d\u2019Hebron, Barcelona, Spain"},{"name":"Vall d\u2019Hebron Research Institute, Autonomous University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Soques","sequence":"first","affiliation":[{"name":"Paediatric Oncology and Haematology Department, University Hospital Vall d\u2019Hebron, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Isabel","family":"Benitez-Carabante","sequence":"first","affiliation":[{"name":"Paediatric Oncology and Haematology Department, University Hospital Vall d\u2019Hebron, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Gonzalez-Amores","sequence":"first","affiliation":[{"name":"Paediatric Infectious Diseases and Immunodeficiencies Unit, University Hospital Vall d\u2019Hebron, Barcelona, Spain"},{"name":"Vall d\u2019Hebron Research Institute, Autonomous University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurora","family":"Fernandez-Polo","sequence":"first","affiliation":[{"name":"Vall d\u2019Hebron Research Institute, Autonomous University of Barcelona, Barcelona, Spain"},{"name":"Pharmacy Department, University Hospital Vall d\u2019Hebron, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berta","family":"Renedo","sequence":"first","affiliation":[{"name":"Pharmacy Department, University Hospital Vall d\u2019Hebron, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8119-8749","authenticated-orcid":false,"given":"Maria Teresa","family":"Martin","sequence":"first","affiliation":[{"name":"Vall d\u2019Hebron Research Institute, Autonomous University of Barcelona, Barcelona, Spain"},{"name":"Microbiology Department, University Hospital Vall d\u2019Hebron, Barcelona, Spain"},{"name":"Autonomous University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0346-5570","authenticated-orcid":false,"given":"Pere","family":"Soler-Palacin","sequence":"first","affiliation":[{"name":"Paediatric Infectious Diseases and Immunodeficiencies Unit, University Hospital Vall d\u2019Hebron, Barcelona, Spain"},{"name":"Vall d\u2019Hebron Research Institute, Autonomous University of Barcelona, Barcelona, Spain"},{"name":"Autonomous University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Diaz-de-Heredia","sequence":"first","affiliation":[{"name":"Vall d\u2019Hebron Research Institute, Autonomous University of Barcelona, Barcelona, Spain"},{"name":"Paediatric Oncology and Haematology Department, University Hospital Vall d\u2019Hebron, Barcelona, Spain"},{"name":"Autonomous University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,4,26]]},"reference":[{"key":"2020042619354986500_dkaa149-B1","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/00006454-200203000-00013","article-title":"Infections diagnosed in the first year after pediatric stem cell transplantation","volume":"21","author":"Benjamin","year":"2002","journal-title":"Pediatr Infect Dis J"},{"key":"2020042619354986500_dkaa149-B2","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.hemonc.2017.05.013","article-title":"Complications of hematopoietic stem transplantation: fungal infections","volume":"10","author":"Omrani","year":"2017","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"2020042619354986500_dkaa149-B3","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/jpids\/pix030","article-title":"Risk factors for invasive fungal disease in pediatric cancer and hematopoietic stem cell transplantation: a systematic review","volume":"7","author":"Fisher","year":"2018","journal-title":"J Pediatric Infect Dis Soc"},{"key":"2020042619354986500_dkaa149-B4","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/sj.bmt.1705113","article-title":"Risks and outcomes of invasive fungal infections in pediatric patients undergoing allogeneic hematopoietic cell transplantation","volume":"36","author":"Dvorak","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"2020042619354986500_dkaa149-B5","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.bbmt.2015.03.018","article-title":"Epidemiology, management, and outcome of invasive fungal disease in patients undergoing hematopoietic stem cell transplantation in China: a multicenter prospective observational study","volume":"21","author":"Sun","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"2020042619354986500_dkaa149-B6","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/sj.bmt.1702654","article-title":"Invasive fungal infections in pediatric bone marrow transplant recipients: single center experience of 10 years","volume":"26","author":"Hovi","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"2020042619354986500_dkaa149-B7","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1097\/MPH.0b013e318142b598","article-title":"Evaluation of risk factors for invasive fungal infection after allogeneic stem cell transplantation in pediatric patients","volume":"29","author":"Kobayashi","year":"2007","journal-title":"J Pediatr Hematol Oncol"},{"key":"2020042619354986500_dkaa149-B8","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1038\/s41409-018-0160-2","article-title":"Risk factors associated with development and mortality by invasive fungal diseases in pediatric allogeneic stem cell transplantation. A pediatric subgroup analysis of data from a prospective study of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO)","volume":"53","author":"Castagnola","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"2020042619354986500_dkaa149-B9","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1016\/S1470-2045(14)70017-8","article-title":"Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation","volume":"15","author":"Groll","year":"2014","journal-title":"Lancet Oncol"},{"key":"2020042619354986500_dkaa149-B10","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1093\/infdis\/171.6.1545","article-title":"Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation\u2014a prospective, randomized, double-blind study","volume":"17","author":"Slavin","year":"1995","journal-title":"J Infect Dis"},{"key":"2020042619354986500_dkaa149-B11","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.cmi.2019.05.019","article-title":"ESCMID-ECMM guideline: diagnosis and management of invasive aspergillosis in neonates and children","volume":"25","author":"Warris","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"2020042619354986500_dkaa149-B12","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/bmt.2010.256","article-title":"Antifungal prophylaxis in hematopoietic stem cell transplant recipients: the unfinished tale of imperfect success","volume":"46","author":"Kontoyiannis","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"2020042619354986500_dkaa149-B13","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1086\/422312","article-title":"Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation","volume":"39","author":"van Burik","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2020042619354986500_dkaa149-B14","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1007\/s12185-008-0196-y","article-title":"Use of micafungin versus fluconazole for antifungal prophylaxis in neutropenic patients receiving hematopoietic stem cell transplantation","volume":"88","author":"Hiramatsu","year":"2008","journal-title":"Int J Hematol"},{"key":"2020042619354986500_dkaa149-B15","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/1471-2334-12-151","article-title":"Caspofungin as antifungal prophylaxis in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective analysis","volume":"12","author":"D\u00f6ring","year":"2012","journal-title":"BMC Infect"},{"key":"2020042619354986500_dkaa149-B16","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/pbc.21239","article-title":"Liposomal amphotericin B prophylaxis of invasive mold infections in children post allogeneic stem cell transplantation","volume":"50","author":"Roman","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"2020042619354986500_dkaa149-B17","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1159\/000083447","article-title":"Haemopoietic cell transplantation of patients with a history of deep or invasive fungal infection during prophylaxis with liposomal amphotericin B","volume":"113","author":"de Wit","year":"2005","journal-title":"Acta Haematol"},{"key":"2020042619354986500_dkaa149-B18","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s40265-016-0538-7","article-title":"Liposomal amphotericin B (AmBisome\u00ae): a review of the pharmacokinetics, pharmacodynamics, clinical experience and future directions","volume":"76","author":"Stone","year":"2016","journal-title":"Drugs"},{"key":"2020042619354986500_dkaa149-B19","doi-asserted-by":"crossref","first-page":"e01477","DOI":"10.1128\/AAC.01477-16","article-title":"Safety, tolerability and pharmacokinetics of liposomal amphotericin B in immunocompromised pediatric patients","volume":"61","author":"Seibel","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2020042619354986500_dkaa149-B20","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1111\/imj.12595","article-title":"Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2014","volume":"44","author":"Grigg","year":"2014","journal-title":"Intern Med J"},{"key":"2020042619354986500_dkaa149-B21","doi-asserted-by":"crossref","first-page":"685","DOI":"10.2165\/11599810-000000000-00000","article-title":"Antifungal chemoprophylaxis in children and adolescents with haematological malignancies and following allogeneic haematopoietic stem cell transplantation: review of the literature and options for clinical practice","volume":"72","author":"Tragiannidis","year":"2012","journal-title":"Drugs"},{"key":"2020042619354986500_dkaa149-B22","first-page":"577","article-title":"Randomized double-blind study of liposomal amphotericin B (Ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients","volume":"12","author":"Tollemar","year":"1993","journal-title":"Bone Marrow Transplant"},{"key":"2020042619354986500_dkaa149-B23","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/sj.bmt.1701543","article-title":"Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study","volume":"23","author":"Kelsey","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"2020042619354986500_dkaa149-B24","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","article-title":"Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2020042619354986500_dkaa149-B25","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/myc.12960","article-title":"Defining breakthrough invasive fungal infection\u2014Position paper of the mycoses study group education and research consortium and the European Confederation of Medical Mycology","volume":"62","author":"Cornely","year":"2019","journal-title":"Mycoses"},{"key":"2020042619354986500_dkaa149-B26","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00007890-197410000-00001","article-title":"Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors","volume":"18","author":"Glucksberg","year":"1974","journal-title":"Transplantation"},{"key":"2020042619354986500_dkaa149-B27","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/bmt.2013.136","article-title":"Predictors of invasive fungal infection in pediatric allogeneic hematopoietic SCT recipients","volume":"49","author":"Hol","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"2020042619354986500_dkaa149-B28"},{"key":"2020042619354986500_dkaa149-B29","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1093\/jac\/dkx263","article-title":"Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease","volume":"72","author":"Cornely","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2020042619354986500_dkaa149-B30","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/myc.13029","article-title":"Epidemiology, utilisation of healthcare resources and outcome of invasive fungal diseases following paediatric allogeneic haematopoietic stem cell transplantation","volume":"63","author":"Linke","year":"2020","journal-title":"Mycoses"},{"key":"2020042619354986500_dkaa149-B31","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1093\/annonc\/mdl128","article-title":"Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized, single-center trial","volume":"17","author":"Penack","year":"2006","journal-title":"Ann Oncol"},{"key":"2020042619354986500_dkaa149-B32","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1111\/j.1469-0691.2011.03483.x","article-title":"Liposomal amphotericin B twice weekly as antifungal prophylaxis in paediatric haematological malignancy patients","volume":"17","author":"Bochennek","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"2020042619354986500_dkaa149-B33","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1097\/INF.0000000000000335","article-title":"Safety and tolerability of high-dose weekly liposomal amphotericin B antifungal prophylaxis","volume":"33","author":"Hand","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"2020042619354986500_dkaa149-B34","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1093\/jac\/dkp196","article-title":"Safety, tolerance and outcome of treatment with liposomal amphotericin B in paediatric patients with cancer or undergoing haematopoietic stem cell transplantation","volume":"64","author":"Kolve","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"2020042619354986500_dkaa149-B35","doi-asserted-by":"crossref","first-page":"5111","DOI":"10.1182\/blood-2010-02-268151","article-title":"Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation","volume":"116","author":"Wingard","year":"2010","journal-title":"Blood"},{"key":"2020042619354986500_dkaa149-B36","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/MPH.0000000000000926","article-title":"Voriconazole antifungal prophylaxis in children with malignancies: a nationwide study","volume":"40","author":"Pana","year":"2018","journal-title":"J Pediatr Hematol Oncol"},{"key":"2020042619354986500_dkaa149-B37","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/QCO.0000000000000502","article-title":"Invasive fungal disease and cytomegalovirus infection: is there an association?","volume":"31","author":"Yong","year":"2018","journal-title":"Curr Opin Infect Dis"},{"key":"2020042619354986500_dkaa149-B38","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1086\/338624","article-title":"High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection","volume":"185","author":"Nichols","year":"2002","journal-title":"J Infect Dis"},{"key":"2020042619354986500_dkaa149-B39","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/sj.bmt.1702243","article-title":"Amphotericin B colloidal dispersion (Amphocil) vs fluconazole for the prevention of fungal infections in neutropenic patients: data of a prematurely stopped clinical trial","volume":"25","author":"Timmers","year":"2000","journal-title":"Bone Marrow Transplant"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/advance-article-pdf\/doi\/10.1093\/jac\/dkaa149\/33130102\/dkaa149.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/advance-article-pdf\/doi\/10.1093\/jac\/dkaa149\/33130102\/dkaa149.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T06:26:35Z","timestamp":1695968795000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/advance-article\/doi\/10.1093\/jac\/dkaa149\/5825464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,26]]},"references-count":39,"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaa149","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,26]]},"article-number":"dkaa149"}}